GLP 1s effectiveness at blood pressure control on par with traditional anti hypertensives, tracks well with % weight loss. In someone with hypertension due to their underlying obesity, why not Michael Weintraub, MD Innovent Dosed First Participant in Phase 3 Clinical Study (GLORY 2) of Mazdutide (IBI362) Higher Dose 9 mg in Chinese Adults with Obesity Once weekly mazdutide, a glucagon like peptide 1 and glucagon receptor dual agonist, provided clinically relevant reduction in body weight in Chinese adults with obesity or overweight. Full GLORY 1 trial results: https: nej.md 4koUvaP Emerging incretin and multi agonist based treatments the continued refinement and continuous expansion of a potent therapeutic armamentarium for cardio kidney liver metabolic diseases and beyond Metabolism Clinical and Experimental